Sclerotherapy with polidocanol microfoam in head and neck venous and lymphatic malformations

• Published in: Acta otorhino-laryngologica italica 2022-04, Vol.42 (2), p.116-125
• Main Authors: De Corso, Eugenio, Cina, Alessandro, Salonna, Giampiero, Di Cintio, Giovanni, Gaudino, Simona, Panfili, Marco, Colosimo, Cesare, Paludetti, Gaetano
• Format: Article
• Language: English
• Subjects: Head; Head and Neck; Humans; Lymphatic Abnormalities - drug therapy; Neck; Polidocanol - therapeutic use; Retrospective Studies; Sclerosing Solutions - therapeutic use; Sclerotherapy; Treatment Outcome; Vascular Malformations - therapy
• ISSN: 1827-675X; 0392-100X; 1827-675X
• DOI: 10.14639/0392-100X-N1310

Polidocanol sclerotherapy of head and neck venous malformations (VMs) and lymphatic malformations (LMs) has been reported only in limited series. In this manuscript we evaluated the efficacy and safety of polidocanol sclerotherapy in a series of head and neck venous and lymphatic malformations. This retrospective observational study analysed data on 20 head and neck VMs and LMs that underwent to percutaneous or endoscopic intra-lesional 3% polidocanol microfoam sclerotherapy at our institution. Clinical response was ranked as excellent, moderate and poor based on volume reduction by MRI and resolution of symptoms. The median volume decreased from 19.3 mL to 5.8 mL after sclerotherapy (mean volume reduction: 72.98 ± 16.1%). An excellent-moderate response was observed in 94.4% of cases. We observed a mean volume reduction of 79.5 ± 16.1 in macrocystic LMs, of 76.1 ± 13.0% in VMs, of 60.5 ± 10.9% in mixed lymphatic ones and 42.5% in microcystic lymphatic ones. Polidocanol sclerotherapy appears to be an effective and safe treatment for venous and lymphatic head and neck malformations. We observed the best responses in macrocystic LMs and VMs, whereas mixed lymphatic ones showed a moderate response and microcystic lymphatic ones a poor response.